Betacellulin (BTC) is a member of the epidermal growth factor (EGF) family, and it acts through EGF receptors. We asked whether BTC could be an angiogenic factor. Using human umbilical vein endothelial cells (HUVECs), we examined the effect of BTC on kinases and angiogenic processes. BTC induced ERK1/2 and Akt phosphorylation in a dose-and time-dependent manner. BTC induced phosphorylation of all three EGF receptors present on HUVECs: ErbB2, ErbB3, and ErbB4. Pretreatment with effective concentrations of ErbB1 inhibitor did not suppress BTC-induced kinase phosphorylation. BTC, EGF, VEGF (all at 10 ng/ml) produced similar increases in DNA synthesis. BTC, EGF, and VEGF all significantly increased endothelial cell migration. In addition, BTC promoted survival in a dose-dependent manner, and its effect was inhibited by pretreatment with PtdIns 3'-kinase inhibitor wortmannin or MEK1/2 inhibitor PD98059. Both BTC and EGF produced similar increases in tube formation in collagen gels. BTC-induced tube formation was suppressed by PD98059, wortmannin, and LY294002. In the mouse Matrigel plug assay, BTC (100 ng/ml) promoted neovessel formation, and its effect was suppressed by a combination of wortmannin and PD98059. Taken together, these data show that BTC exerts potent angiogenic activity through activation of EGF receptors, mitogen-activated protein kinase, and PtdIns 3'-kinase/Akt in endothelial cells.
through the activation of ErbB2, ErbB3, and ErbB4 receptors acting on the intracellular MAPK and phosphatidylinositol 3'-kinase (PtdIns 3'-kinase)/Akt pathways.
MATERIALS AND METHODS

Materials and cell culture
Recombinant human BTC was purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human EGF and vascular endothelial growth factor (VEGF) were purchased from R&D Systems (Minneapolis, MN). ErbB1 inhibitor AG1478, PtdIns 3'-kinase inhibitors wortmannin and LY294002, and mitogen-activated protein/extracellular signal-regulated kinase (MEK) 1/2 inhibitor PD98059 were obtained from Calbiochem (San Diego, CA). Antibodies for phosphospecific ERK1/2 (Thr202/Tyr204) and phospho-specific Akt (Ser473) were purchased form New England Biolabs (Beverly, MA). ErbB1, ErbB2, ErbB3, and ErbB4 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for phospho-ErbB1, phospho-ErbB2, phospho-Erb4, and phospho-tyrosine were received from Upstate Biotechnology (Lake Placid, NY). Matrigel, cell culture products, ands most other biochemical reagents were purchased from Sigma-Aldrich, unless otherwise specified. HUVECs and human umbilical artery vascular smooth muscle cells (HUAVSMCs) were prepared from human umbilical cords by collagenase digestion and maintained as described previously (27) . The primary cultured cells used in this study were between passage 2 and 3.
Biochemical analyses
HUVECs were incubated in M-199 medium with 1% fetal bovine serum (FBS) for 16 h before addition of the indicated growth factors. To measure MAPK activity, Akt (Ser473) phosphorylation, and ErbB2 and ErbB4 phosphorylation, HUVECs were treated with BTC for the indicated times and doses. The treated HUVECs were washed two times with phosphatebuffered saline (PBS), dissolved in sample buffer (50 mM Tris-HCl, 100 mM NaCl, 0.1% sodium dodecyl sulfate [SDS] , 1% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 µg/ml aprotinin, 1 µg/ml pepstatin, and 1 µg/ml leupeptin), boiled, separated by SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membrane. The membranes were treated and the phosphorylation levels analyzed according to the manufacturer's protocol {New England BioLabs for extracellular signal-regulated kinase (ERK)1/2 and Akt (Ser4730); Upstate Biotechnology for ErbB2 and ErbB4). To measure the phosphorylation of ErbB3, 1.0 mg of cell lysate protein was immunoprecipitated with anti-ErbB3 (Santa Cruz Biotechnology).
Immunoprecipitates were Western blotted with anti-phosphotyrosine antibody (Upstate Biotechnology), and the membrane was reprobed with anti-ErbB3 antibody to verify equal loading of protein in each lane. All signals were visualized and analyzed by densitometric scanning (LAS-1000, Fuji Film, Tokyo).
Assays of DNA synthesis, migration, and survival
The DNA synthetic activity of HUVECs was measured as described previously (28) . In brief, HUVECs were plated onto gelatinized 24-well plates at a density of 2 × 10 4 cells/cm 2 in M-199 medium supplemented with 20% (vol/vol) fetal bovine serum (FBS). The cells were cultured for 12 h. Then the medium was changed and growth factors (or control buffer) were added in M-199 medium supplemented with 2% FBS. After 24 h, fresh medium and growth factors were added and the cells were incubated for an additional 24 h. The cells were washed twice with PBS, and the DNA amount was measured with PicoGreen fluorescent reagent (Molecular Probes, Eugene, OR) according to the method described by Singer et al. (29) , using a fluorescence spectrometer equipped with a microplate reader (Molecular Device, Sunnyvale, CA).
The migration assay in HUVECs was performed using a modified Boyden chamber (Neuroprobe, Cabin John, MD) as described previously (30) . Growth factors in M199 containing 1% bovine serum albumin were placed in the bottom wells of the chamber. Polycarbonate filters with 8-µm pores (Poretics, Livermore, CA) were coated with 50 µg/ml fibronectin and 0.2% gelatin and placed between the test substances and the upper chambers. Cells were trypsinized, washed twice in M199, and resuspended in M199 containing 1% bovine serum albumin. We placed 2 × 10 5 cells into each well in the upper chamber and incubated them for 6 h at 37°C in a humidified chamber with 5% CO 2 . After incubation, the nonmigrated cells were removed from the upper side of the filters with a cotton ball. The filters were fixed with methanol, mounted onto microscope slides, and stained with Diff-Quik solution. Using a microscope, we counted the migrated cells at 100× magnification.
To induce apoptosis, HUVECs were plated onto gelatinized 24-well plates (7 × 10 4 cells per well) in M-199 containing 20% FBS and incubated for 12 h. Then the wells were extensively washed with PBS, and the medium was changed to serum-free M-199 containing control buffer, BTC, and EGF and incubated for 30 h. Floating apoptotic cells were collected with two washes in PBS. Adherent cells were collected by trypsinization. All cells were stained with the annexin-V-fluos staining kit (Roche Molecular Biochemicals, Mannheim, Germany) for 15 min at 20°C. Following staining of annexin-V and propidium iodide (PtdIns), the cells were analyzed on a flow cytometer and data were analyzed with CellQuest software (Becton Dickinson, Franklin Lakes, NJ).
In vitro and in vivo angiogensis
In vitro tube formation was performed in 3-D cultures of HUVECs on gel matrices with rat tail collagen (type I, Roche Molecular Biochemicals) at a final concentration of 1.75 mg/ml. The collagen solution was prepared in M-199 culture medium and adjusted to fibronectin (90 mg/ml), 150 mM HEPES, and sodium bicarbonate, neutralizing the pH by the addition of 1 M NaOH. HUVECs were added immediately to a final concentration of 2 × 10 6 cells/ml. Drops (0.2 ml each) of the cell-collagen mixture were added to 24-well dishes and placed in a humidified CO 2 incubator at 37°C for 2-5 min, allowing them to solidify. The medium was supplemented with 5% FBS with or without BTC and indicated kinase inhibitors. BTC and kinase inhibitor were replenished every 24 h. Tube formation in each well was monitored, and photos were taken at 48 h using an inverted microscope (Zeiss, Gottingen, Germany). A Matrigel plug assay was performed as described previously (31) . In brief, C57/BL6 mice were injected s.c. with 0.5 ml of Matrigel with heparin (50 U/ml) that contained control buffer, BTC, or BTC plus wortmannin and PD98059. All three gels were injected into the same animal at different locations of flank in order to avoid individual variance. Each portion of injected Matrigel rapidly formed a single solid gel plug. After 2 wk, mice were killed, and the Matrigel plugs were recovered, fixed with 4% paraformaldehyde in PBS, embedded in paraffin, sectioned, and stained with MasonTrichrome solution for microscopic observation. To quantify the formation of functional neovessels in Matrigel, the amount of hemoglobin in each plug was assayed according to the manufacturer's protocol (Drabkin reagent kit 525, Sigma-Aldrich).
Data analyses
Data are expressed as mean ±SD. Statistical significance was tested using one-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at P<0.05.
RESULTS
BTC induces ERK1/2 and Akt phosphorylations
Activation of MAPK and Akt in endothelial cells plays a crucial role in angiogenesis (32) (33) (34) . To measure MAPK activity, we measured the phosphorylation of two MAPKs, ERK1 (p44 MAPK ) and ERK2 (p42 MAPK ). BTC (10 ng/ml) increased ERK1/2 phosphorylation as early as 1 min and produced a maximal effect at 5 min (Fig. 1A) . These effects declined and returned to control levels at 60 min. The maximum mean increase in ERK2 phosphorylation was 7.9-fold. BTC (0.3-10 ng/ml) increased ERK1/2 phosphorylation in a dose-dependent manner (Fig. 1B) . Both BTC (10 ng/ml) and EGF (10 ng/ml) produced a similar level of ERK2 phosphorylation at 5 min ( Fig. 1A and 1B ). To measure Akt activity, we measured the phosphorylation of Akt (Ser473). BTC (10 ng/ml) increased Akt phosphorylation as early as 1 min and produced a maximal effect at 5 min (Fig. 1C ). These effects declined and returned to control levels at 30 min. The maximum mean increase in Akt phosphorylation was 4.9-fold. BTC (0.3-10 ng/ml) increased Akt phosphorylation in a dose-dependent manner (Fig. 1D ). In addition, pretreatment of PtdIns 3'-kinase specific inhibitor, wortmannin (30 nM), completely abolished the BTC-induced Akt phosphorylation (data not shown). Both BTC (10 ng/ml) and EGF (10 ng/ml) produced a similar level of Akt phosphorylation at 5 min ( Fig. 1C and 1D ).
BTC-induced MAPK and Akt activations are mediated through ErbB2, ErbB3, and ErbB4 receptors
Because BTC exerts biological effects through ErbB receptors, we next examined the distribution of subtypes of EGF receptors in primary cultures of HUVECs. Our Western blot analyses indicate that HUVECs have three ErbB receptors, ErbB2, ErbB3, and ErbB4, whereas HUAVSMCs have all four ErbB receptors, ErbB1, ErbB2, ErbB3, and ErbB4 ( Fig. 2A) . Russel et al. found the same distribution of EGF receptors in HUVECs (23) . Furthermore, BTC (10 ng/ml) phosphorylated all three receptors in HUVECs: ErbB2, ErbB3, and ErbB4 ( Fig. 2B and  2C ). These results indicated that BTC activated MAPK and Akt in HUVECs mainly through three ErbB receptors: ErbB2, ErbB3, and ErbB4. AG1478 is a potent and selective inhibitor on ErbB1 (IC 50 =3 nM) but does not inhibit ErbB2 (IC 50 >100 µM). It has not been characterized on ErbB3 and ErbB4. Pretreatment with AG1478 at 1.0 and 10 nM (the effective concentration to inhibit ErbB1) did not change BTC-induced ERK1/2 and Akt phosphorylation (Fig. 2D) . However, pretreatment of AG1478 at higher concentrations suppressed BTC-induced ERK1/2 and Akt phosphorylation. These results support the idea that phosphorylation of ERK1/2 and Akt by BTC is not mediated through ErbB1.
BTC increases DNA synthesis and migration in endothelial cells
MAPK and PtdIns 3'-kinase/Akt participate in protein kinase cascades that play critical roles in the regulation of cell growth and migration (32) (33) (34) . Because BTC-induced ERK1/2 and Akt activation might be involved in proliferation and migration in endothelial cells, we examined the effect of BTC on endothelial cell DNA synthesis and migration. After 30 h treatment of HUVECs, BTC (10 ng/ml) increased DNA synthesis an average of 1.3-fold, whereas EGF (10 ng/ml) and VEGF (10 ng/ml) both increased DNA synthesis ~1.4-fold (Fig. 3A) . After 6 h treatment of HUVECs, BTC (10 ng/ml) increased migration ~1.4-fold, whereas EGF (10 ng/ml) and VEGF (10 ng/ml) increased DNA synthesis ~1.4-fold and 1.9-fold, respectively (Fig. 3B) .
BTC enhances survival in endothelial cells
Endothelial cell survival is a prerequisite for DNA synthesis and migration. Because activation of MAPK and PtdIns 3'-kinase/Akt is often involved in survival of endothelial cells (27, 32, 35, 36) , we examined the effect of BTC on endothelial survival. Serum deprivation caused apoptosis in HUVECs, evidenced by more floating and less adherent cells seen at 24 h with phase-contrast microscopy ( Fig. 4A) . Addition of BTC (10 ng/ml) or EGF (10 ng/ml) reduced the number of serum deprivation-induced floating cells. Our FACS analyses indicated that 35-45% of the cells were dead by apoptosis at 30 h after serum deprivation (Fig. 4B) . Addition of BTC (10 ng/ml) or EGF (10 ng/ml) inhibited ~45-55% of these apoptotic events ( Fig. 4B and 4C ). In addition, BTC (0.1-10 ng/ml) inhibited the apoptotic events in a dose-dependent manner (Fig. 4C) . Furthermore, pretreatment of MEK1/2 inhibitor PD98059 or PtdIns 3'-kinase inhibitor wortmannin partially inhibited the BTC-induced survival effect. However, combined pretreatment of PD98059 and wortmannin completely inhibited the BTC-induced survival effect. These results indicate that BTC exerts its antiapoptotic effect in endothelial cells through activation of MAPK and PtdIns 3'-kinase/Akt.
BTC induces tube formation by endothelial cells in collagen gel
Endothelial cells form as a precursor to blood vessel formation (37) . Well-known endothelial growth factors, including VEGF and angiopoietin-1, increase tube formation of endothelial cells through enhanced migration (30, 38, 39) . Because our data indicated that BTC is a relatively strong enhancer for migration, we examined the effect of BTC on tube formation of HUVECs in type I collagen gel. After 48 h, BTC (10 ng/ml), EGF (10 ng/ml), and VEGF (10 ng/ml) increased tube formation ~3.7-fold, 5.5-fold, and 6.3-fold, respectively. ErbB receptor inhibitor AG1478, MEK1/2 inhibitor PD98059, and PtdIns 3'-kinase inhibitors wortmannin and LY294002 suppressed BTC-induced tube formation to varying degrees ( Fig. 5A and 5B). The inhibitors alone mildly suppressed basal tube formation at 48 h. These data suggested that BTCinduced tube formation in endothelial cells is mediated through activation of ErbB receptors, MAPK, and PtdIns 3'-kinase.
BTC promotes angiogenesis in vivo
To determine whether BTC is capable of promoting angiogenesis in vivo, we performed an established in vivo angiogenesis model, the mouse Matrigel plug assay. At day 14, Matrigel containing BTC (100 ng/ml) produced more neovessels within gels than Matrigel containing control buffer (Fig. 6A) . Histochemical examination indicated that the neovessels contained red blood cells (Fig. 6B) . At day 5, Matrigel containing BTC (100 ng/ml) had more hemoglobin content than Matrigel containing control buffer (Fig. 6C) . Addition of PD98059 and wortmannin suppressed these BTC-induced angiogenic activity. When quantified by measurement of hemoglobin in the Matrigels, the angiogenic activity of BTC (100 ng/ml) was comparable to that of 100 ng/ml of EGF or 20 ng/ml of VEGF (data not shown). Thus, BTC has a potent angiogenic activity in vivo through activation of MAPK and PtdIns 3'-kinase. 
DISCUSSION
In this report, we demonstrate that BTC has a novel function as an angiogenic factor. BTC is a strong activator for intracellular MAPK and Akt in endothelial cells through ErbB2, ErbB3, and ErbB4 receptors. The activation amplitude of MAPK and Akt by BTC is comparable to the activation amplitude of MAPK and Akt by EGF. Accordingly, BTC promoted endothelial DNA synthesis, migration, and survival, which are the essential steps for angiogenesis. Indeed, BTC promoted tube formation in vitro and neovessel formation in vivo in gel plugs. Thus, we demonstrate here a novel biological function of BTC in angiogenesis (Fig. 7) , in addition to the regulatory functions previously identified in pancreas and intestine.
Activation of MAPK and activation of PtdIns 3'-kinase/Akt in endothelial cells are crucial intracellular signaling steps for angiogenesis (32) (33) (34) . Growth factors bind to their receptor tyrosine kinases in endothelial cells and induce angiogenesis through activation of these kinases (30, (32) (33) (34) 40) . BTC is known to bind to ErbB1 and ErbB4 homodimers, and also heterodimers of ErbB1/ErbB2, ErbB1/ErbB3, ErbB1/ErbB4, ErbB2/ErbB3, and ErbB2/ErbB4 (11). Our Western blot analyses indicate that primary cultured HUVECs express ErbB2, ErbB3, and ErbB4, but not ErbB1. In addition, our biochemical results indicate that BTC induces phosphorylation of ErbB2, ErbB3, and ErbB4. Moreover, BTC-induced phosphorylation of MAPK and Akt is not suppressed by a selectively inhibitory concentration of ErbB1 receptor. Therefore, BTC-induced activation of MAPK and Akt could occur through activation of ErbB4 homodimer, ErbB2/ErbB3, or ErbB2/ErbB4 heterodimers.
Angiogenesis is essential for tumor growth and maintenance (41, 42) . The angiogenic process is a tightly regulated phenomenon that begins with at least the four following steps (37): 1) proliferation of endothelial cells, 2) enzymatic degradation of basement membrane and interstitial matrices by endothelial cells, 3) migration of endothelial cells, and 4) formation of a blood vessel tube from sprouting endothelial cells. Angiogenesis can be induced by activation of endothelial receptor tyrosine kinases, including EGF receptors. Upon activation of EGF receptors by the binding of EGF family ligands, there is an induction of proliferation, proteolytic enzyme secretion, migration, and tube formation in endothelial cells. Therefore, we next examined the effect of BTC on these biological changes in endothelial cells by using in vitro angiogenesis assays. Our results indicate that BTC increased DNA synthesis, migration, and tube formation. It is well known that endothelial cell survival is an essential prerequisite for DNA synthesis and migration. Our results indicated that BTC is also a strong endothelial cell survival factor. We also confirmed the angiogenic activity of BTC by performing an in vivo mouse Matrigel plug assay. BTC highly promoted neovessel formation in the Matrigel plug, and we noted that these newly synthesized vessels participated actively in the circulation of blood cells. Moreover, our pharmacological inhibition study indicated that the activation of MAPK and PtdIns 3'-kinase/Akt by BTC is crucial in endothelial cell survival, tube formation, and neovessel formation in the Matrigel plug. Thus, taken together, these data show that BTC is a strong angiogenic growth factor through intracellular MAPK and PtdIns 3'-kinase/Akt activation.
Angiogenesis is an essential process in tumor-host interactions for tumor growth, maintenance ,and metastasis (41, 42) . EGF family ligands and their receptors are closely involved in tumor progression and tumor angiogenesis (24) (25) (26) . Because recent reports indicate that EGF receptors are closely involved in tumor angiogenesis through induction of angiogenic molecules such as VEGF and angiopoietin-1 (43) (44) (45) (46) , BTC, in addition to having a direct angiogenic role, may also act as an indirect angiogenic factor through induction of angiogenic molecules in vivo. Like other cancers, pancreatic cancer also has an extensive interaction with host cells for progressive growth and metastasis. Notably, BTC expression is elevated approximately sevenfold in 9 out of 10 pancreatic cancers compared with normal pancreas (9). Moreover, expression of EGF receptors is enhanced in pancreatic cancers (47) . In the context of pancreatic cancers, BTC would be not only a significant growth factor for pancreatic cancer cells, but also a strong angiogenic growth factor and endothelial cell survival factor. As expected, most pancreatic cancer is characterized by highly angiogenic, extensive local invasion and early hematogenous metastasis (48) . In fact, a blockade of EGF receptors using the corresponding kinase inhibitor significantly inhibited growth and metastasis of human pancreatic cancer growing orthotopically in nude mice (49, 50) . The therapeutic effect was mediated in part by inhibition of tumor angiogenesis and increased apoptosis of tumor-associated endothelial cells. In addition, a blockade of EGF receptors using a blocking antibody or its kinase inhibitor has emerged as a novel approach in the treatment of cancer (51) .
In summary, we demonstrated here that BTC could be a strong angiogenic factor because it induces cell survival, DNA synthesis, migration, and tube formation in endothelial cells and neovessel formation in vivo. These angiogenic effects are mediated mainly through ErbB2, ErbB3, and ErbB4 receptors; MAPK; and PtdIns 3'-kinase/Akt in endothelial cells. Thus, in addition to the regulatory functions previously identified in pancreas and intestine, BTC has a novel biological function in vascular endothelial cells. Miyagawa, J., Hanafusa, O., Sasada, R., Yamamoto, K., Igarashi, K., Yamamori, K., Seno, M., Tada, H., Nammo, T., Li, M., Yamagata, K., Nakajima, H., Namba, M., Kuwajima endothelial cells (HUVECs) were plated in M199 supplemented with 20% serum. After 12 h in culture, the control buffer (CB), BTC (10 ng/ml), epidermal growth factor (EGF) (10 ng/ml), or vascular endothelial growth factor (VEGF) (10 ng/ml) was added in M-199 medium supplemented with 2% serum. At 48 h, the DNA amount was measured with PicoGreen fluorescent reagent. B) CB, BTC (10 ng/ml), EGF (10 ng/ml), or VEGF (10 ng/ml) in M199 containing 1% bovine serum albumin was placed in the bottom wells of the chamber. HUVECs (2.0 × 10 5 ) were placed in the upper chamber, then incubated for 6 h at 37°C. The migrated cells were stained with Diff-Quik solution and counted at 100× magnification using a microscope. Bars represent the mean ± SD from four or five experiments. *P<0.05 vs. CB. h in the presence of the indicated combinations of: control buffer (CB), BTC (10 ng/ml), AG1478 (100 nM, AG), PD98059 (PD, 2 µM), wortmannin (30 nM, WT), LY294002 (100 nM, LY), epidermal growth factor (EGF) (10 ng/ml), and vascular endothelial growth factor (VEGF) (10 ng/ml). Growth factors and kinase inhibitor were replenished every 24 h. Endothelial tube formation was assayed in 3-D matrices with type I collagen gel as described in Materials and Methods. A) Representative phase-contrast photographs of capillary-like tube formation in collagen gel. Note that BTC induced more tube formation than CB, but less than EGF or VEGF. BTC-induced tube formation is suppressed by an addition of kinase inhibitor. B) Quantification of tube formation. Number of complete tube networks per given area was counted using phase-contrast microscopy. Bars represent the mean ± SD of five experiments. *P<0.05 vs. CB; # P<0.05 vs. BTC (10 ng/ml). 
